[A23-16] Voclosporin (lupus nephritis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2023
Project no.:
A23-16
Commission:
Commission awarded on 27.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Kidneys and urinary system
Indication:
Adults with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.